All In Biotech

Drug Trial Radar · NCT05151744

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 in Combination With Ranibizumab Administered Intravitreally in Patients With Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

187

Actual

Start

Dec 17, 2021

Primary completion

Apr 17, 2024

Study completion Oct 1, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of vamikibart in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 76 weeks.

Conditions

  • Diabetic Macular Edema

Interventions

  • VamikibartDrug

    Vamikibart will be administered by IVT injection in the study eye.

  • RanibizumabDrug

    Ranibizumab will be administered by IVT injection in the study eye.

  • Sham ProcedureOther

    Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve ParticipantsTime frame: Baseline, Week 44 and Week 48

Locations

38 sites in 9 countries. Site status is shown where the registry gives one.

  • Win Retina

    Arcadia, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Florida Eye Associates

    Melbourne, Florida

  • Retina Vitreous Associates of Florida

    Tampa, Florida

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Deep Blue Retina PLLC

    Southaven, Mississippi

  • Verum Research LLC

    Eugene, Oregon

  • Texas Retina Associates

    Arlington, Texas

  • Retina Consultants of Texas

    Bellaire, Texas

  • Organizacion Medica de Investigacion

    Buenos Aires, Argentina

  • Centro Oftalmológico Dr. Charles S.A.

    Capital Federal, Argentina

  • Oftalmos

    Capital Federal, Argentina

  • Buenos Aires Mácula

    Ciudad Autonoma Buenos Aires, Argentina

  • Grupo Laser Vision

    Rosario, Argentina

  • Retina Institute of Ottawa

    Ottawa, Ontario, Canada

  • Toronto Retina Institute

    Toronto, Ontario, Canada

  • Institut De L'Oeil Des Laurentides

    Boisbriand, Quebec, Canada

  • Rambam Medical Center

    Haifa, Israel

  • Hadassah MC

    Jerusalem, Israel

  • Rabin MC

    Petah Tikva, Israel

  • Kaplan Medical Center

    Rehovot, Israel

  • Tel Aviv Sourasky MC

    Tel Aviv, Israel

  • Niepubliczny Zak?ad Opieki Zdrowotnej PRYZMAT-OKULISTYKA

    Gliwice, Poland

  • Centrum Medyczne UNO-MED

    Krakow, Poland

  • Centrum Diagnostyki i Mikrochirurgii Oka LENS

    Olsztyn, Poland

  • Caminomed

    Tarnowskie Góry, Poland

  • Emanuelli Research and Development Center LLC

    Arecibo, Puerto Rico

  • Pusan National University Hospital

    Busan, South Korea

  • Yeungnam University Medical Center

    Daegu, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Kim's Eye Hospital

    Seoul, South Korea

  • Clinica Universitaria de Navarra

    Madrid, Spain

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, Spain

  • Gloucestershire Hospitals NHS Foundation Trust

    Gloucestershire, United Kingdom

  • Royal Surrey County Hospital

    Guildford, United Kingdom

  • Kings College Hospital NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.